• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Foghorn Therapeutics Inc (NQ: FHTX )

    6.250 -0.360 (-5.45%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 85,492
    Open 6.490
    Bid (Size) 6.250 (5)
    Ask (Size) 6.330 (4)
    Prev. Close 6.610
    Today's Range 6.200 - 6.610
    52wk Range 2.700 - 9.970
    Shares Outstanding 36,936,886
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -3.10%
    -3.10%
    1 Month
    +17.48%
    +17.48%
    3 Month
    +19.96%
    +19.96%
    6 Month
    +104.25%
    +104.25%
    1 Year
    -19.46%
    -19.46%

    More News

    Read More
    Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics: Q4 Earnings Insights
    Via Benzinga
    FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher
    Via Benzinga
    Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces CFO Departure
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.